The Best 80 Cents You'll Ever Spend

Dear Daily Reckoning Reader, Today I’m excited to tell you about a medical breakthrough that is unprecedented in human history. It’s an amazing new technology that could someday restore the sight of 10 million people worldwide. In fact, this revolutionary breakthrough could eventually improve... and extend... the lives of millions of people on earth. And one tiny California company, priced under 80 cents per share, is at the forefront of this revolutionary medical research. Click here to get details on this explosive penny stock that could significantly advance the field of regenerative medicine — and could make you ridiculously rich. Sincerely, Patrick Cox Agora Financial The Daily Reckoning provides over half a million subscribers with literary economic perspective, global market analysis, and contrarian investment ideas. In short, The Daily Reckoning shows how to live well even in uncertain times. We sent this e-mail to IGNOBLE.EXPERIMENT@arconati.us because you or someone using your e-mail address subscribed to this service. Are you having trouble receiving your Daily Reckoning? You can ensure its arrival in your mailbox by: Whitelisting The Daily Reckoning. To end your Daily Reckoning e-mail subscription, click: Unsubscribe. Nothing in this e-mail should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice. We expressly forbid our writers from having a financial interest in any security they personally recommend to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of a printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. © 2012 Agora Financial, LLC. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the World Wide Web), in whole or in part, is strictly prohibited without the express written permission of Agora Financial, LLC. 808 Saint Paul Street, Baltimore MD 21202.